Two out of ten mice in the LEX-CD8086 group were alive for more than 60 days after tumor challenge, indicating that the immunization with B7 gene-modified LEXs induced strong antileukemia protective immunity, in particular in the LEX-CD8086 group. The gene discussed is CD80; the disease is neoplasm.